C3 Jian Recognized for its Commitment to the National Microbiome Initiative Launched Today

LOS ANGELES, California — May 13, 2016 — C3 Jian, Inc., a private clinical stage biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, announced their participation in the official launch of the National Microbiome Initiative (NMI). C3J is recognized for new efforts to support microbiome science.

Today, the White House Office of Science and Technology Policy (OSTP) will hold an event to announce the official launch of the NMI. During the event, the Administration will announce steps to advance the understanding of microbiome behavior and enable protection and restoration of healthy microbiome function, including by investigating fundamental principles that govern microbiomes across diverse ecosystems, and developing new tools to study microbiomes. A distinguished invitee to the event includes Dr. Wenyuan Shi, C3J’s Founding Scientist, Professor and Chair of Oral Biology at the University of California, Los Angeles (UCLA) School of Dentistry and Professor of Microbiology, Immunology and Molecular Genetics at UCLA David Geffen School of Medicine.

The Fact Sheet announcing the National Microbiome Initiative can be accessed here.

C3J is using its innovative proprietary platform technology referred to as STAMPs (Specifically Targeted Antimicrobial Peptides) to drive its commitment of developing safe and effective pathogen-specific antimicrobials that correct dysbiosis of microbiome communities, including the oral and gut microbiomes. The platform technology allows a STAMP to effectively reengineer the microbiota by selectively killing the targeted disease-causing pathogenic bacteria while sparing the remaining healthy microorganisms within the indigenous or ‘normal’ microflora. This targeted approach represents an enormous improvement over broad-spectrum antibiotics that indiscriminately kill both beneficial and pathogenic bacteria. The result is a microbiome reengineered to restore a healthy ecology with the potential for a lasting therapeutic benefit.

The Company’s lead program, C16G2, is the first peptide therapeutic derived from the STAMP platform technology. C16G2 targets the specific elimination of Streptococcus mutans, and is being developed for the prevention of dental caries in adults, adolescents and pediatrics under an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). C16G2 is currently undergoing Phase 2 multi-center clinical trials. Dental caries is recognized as the most common chronic childhood disease in the United States, five times more common than asthma, and nearly 100 percent of adults have dental caries worldwide.

C3J’s other microbiome program is being developed for Clostridium difficile infection using an orally-administered formulation to deliver a STAMP to the regions of the lower GI tract. The company is planning to file an IND in the first half of 2017. C3J is also using the STAMP platform to conduct R&D into microbial imbalances associated with obesity and vancomycin-resistant enterococci (VRE) infection.

Today’s National Microbiome Initiative launch event, hosted by the White House OSTP, will be live streamed from 1:00-4:00 PM EDT at https://www.whitehouse.gov/live.


About C3 Jian, Inc.
C3 Jian is a clinical stage biotechnology company focused on improving human health through the development and commercialization of targeted, pathogen-specific antimicrobials (STAMPs) that treat and prevent human diseases caused by microbial dysbiosis. The proprietary STAMP platform technology has potential applications to a variety of bacterial infections, and disorders, particularly related to the human microbiome. C3 Jian is based in Los Angeles, California. For more information, please visit www.c3-jian.com.

Media Contact: Todd Patrick (T) 310.665.2928 x242, (Email) tpatrick@c3-jian.com or Pierre Kyme (T) 310.665.2928 x234, (Email) pkyme@c3-jian.com.

Leave a Reply